Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Actisoufre Solution is an over-the-counter (OTC) combination drug developed and marketed by Laboratoires Grimberg. It contains sodium monosulfide (which acts as a source of sulfur) and Saccharomyces cerevisiae yeast extract. The drug is indicated for the treatment of chronic inflammatory conditions of the upper respiratory tract, such as chronic rhinitis and chronic rhinopharyngitis (nasopharyngitis). The sulfur component provides mucolytic, anti-inflammatory, and mild antiseptic properties, while the yeast extract provides vitamins and trace elements that support mucosal healing and local immunity. It is administered locally as a nasal or buccal spray.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium monosulfide + Saccharomyces cerevisiae.